[Immunophenotype analysis of leukemic mantle cell lymphoma]

Area of Science:

• Hematology
• Oncology
• Immunophenotyping

Background:

• Mantle cell lymphoma (MCL) is a challenging mature B-cell neoplasm with poor prognosis, frequently misdiagnosed.
• Diagnosis is complicated by its frequent presentation in the leukemic phase, often identified via flow cytometry and cytogenetics.

Purpose of the Study:

• To investigate the immunophenotypic characteristics of leukemic Mantle cell lymphoma.
• To evaluate the utility of novel biomarkers CD200 and CD148 in differentiating MCL from other chronic B-cell lymphoproliferative diseases.

Main Methods:

• Retrospective analysis of immunophenotype data from 22 leukemic MCL patients.
• Utilized four-color flow cytometry to analyze expression of various cell surface markers (CD3, CD5, CD19, CD20, CD22, CD23, FMC7, CD148, CD200, etc.).
• Confirmed t(11;14) translocation using fluorescence in situ hybridization.

Main Results:

• All patients expressed CD19, CD5, CD20 (high), and monoclonal sIg.
• CD22 was weakly expressed in 17 patients; CD23 in 6; FMC7 in 12.
• CD148 was positive in all 18 patients tested (median MFI: 337), while CD200 showed variable expression (negative in 11, weak in 7).

Conclusions:

• Leukemic Mantle cell lymphoma exhibits atypical immunophenotypes, necessitating comprehensive diagnostic approaches including morphology, immunophenotype, and cytogenetics.
• CD200 and CD148 emerge as potential biomarkers for differentiating MCL from chronic B-cell lymphoproliferative disorders.